Protocol demonstrates an effective immunophenotyping approach for hematological malignancies, suggesting improved outcomes with reduced costs and variability.
High-dimensional cell profiling by cytometry by time of flight (CyTOF) enables simultaneous characterization of rare cell populations but requires many antibodies and is sensitive to staining variability. Here, we present a workflow for immunophenotyping human hematological malignancy samples, reducing costs and minimizing technical variation. We describe steps for sample collection, live-cell barcoding using anti-β2-microglobulin and CD147 antibodies, cell staining, data collection, and subsequent analyses. For complete details on the use and execution of this protocol, please refer to Mikami et al. 1
No takes yet. Share an insight, caveat, or question.
Mikami et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: